Celgene continues to see positive results for blockbuster hopeful Ozanimod

Celgene ($CELG) says that its blockbuster hopeful Ozanimod continued to score well against a placebo arm during the maintenance phase of a trial for ulcerative colitis. The 103 patients who had achieved a clinical response after 8 weeks of therapy continued treatment for an added 24 weeks, and 21% in the 1-mg drug arm achieved or maintain remission at 32 weeks--compared to 6% in the placebo arm. Celgene acquired Ozanimod in its $7.2 billion Receptos buyout last July. The Phase III program is expected to read out in 2017, setting up what Celgene hopes will be an approval for a drug that could earn up to $6 billion a year. Release

Suggested Articles

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.

Annexon has grabbed a healthy $100 million round to take its clinical work closer to the finishing line as it tees up shots on multiple targets.

Researchers have demonstrated that targeting a potassium ion channel called Kv2.1 can protect the brain from neuronal damage after a stroke.